Nextgen Biomed Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXGN.TA research report →
Price Chart
About the company
Nextgen Biomed Ltd focuses on developing external dermatological treatments for psoriasis. The company, which was established in 1990, originally operated under the name Sela Group. Com Ltd.
- CEO
- Harel Hershtik
- IPO
- 2002
- Employees
- 3
- HQ
- Tel Aviv, IL
Get TickerSpark's AI analysis on NXGN.TA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $5.12M
- P/E
- -0.81
- PEG
- -0.01
- P/S
- 0.00
- P/B
- -1.69
- EV/EBITDA
- -1.11
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 305.65%
- ROIC
- 228.12%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-93,000-4550.0%
- Op Income
- $-4,875,000
- Net Income
- $-4,892,000+65.5%
- EPS
- $-0.58+70.3%
- OCF Growth
- +53.2%
- FCF Growth
- +51.2%
- 52W High
- $82.70
- 52W Low
- $0.49
- 50D MA
- $20.14
- 200D MA
- $39.76
- Beta
- 0.70
- RSI (14)
- 48
- Avg Volume
- 22.06K
No earnings-call transcripts are available for NXGN.TA yet.
- Free Float
- 85.4%
- Shares Outstanding
- 10.90M
- Float Shares
- 9.31M
Our NXGN.TA coverage
Recent articles, reports, and earnings notes.
No research on NXGN.TA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NXGN.TA report →